A novel anticancer pharmacological agent targeting mitochondrial complex I. (September 2022)

• Record Type: Journal Article
• Authors: Reyes-Castellanos, Gabriela; Carrier, Alice
• Is Part Of: Trends in pharmacological sciences. Volume 43:Number 9(2022)
• Page Start: 706
• Page End: 708
• Publication Date: 2022-09
• Subjects: mitochondria -- oxidative phosphorylation system -- complex I -- anticancer therapies -- cancer metabolism -- tumor microenvironment; Pharmacology -- Periodicals; Pharmacology -- trends -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Electronic journals; Periodicals; 615.1
• DOI: 10.1016/j.tips.2022.03.007
• Languages: English
• ISSNs: 0165-6147

Abstract

Abstract : Targeting metabolic reprogramming has proven successful in oncology, but this field requires better identification of drugs that inhibit mitochondrial metabolism in cancer cells. Recent work from Dr Wolf's group reveals that the primary target of the antitumor compound SMIP004-7 is mitochondrial complex I (NDUFS2 subunit), inhibition of which promotes anticancer immune surveillance.